Study Result Disclosure Treated As Carefully As FDA Submissions – PhRMA
Executive Summary
Drug companies are approaching their clinical trial results disclosures with the same degree of attention as FDA submissions, Pharmaceutical Research & Manufacturers of America VP-Scientific & Regulatory Affairs Caroline Loew said
You may also be interested in...
Confidential Clinical Trial Database Could Spur Publication – Ex-PhRMA Exec
Creating a database of clinical trial information that would be accessible to journal editors, but not the public, could help encourage companies to publish certain types of trial information, a former Pharmaceutical Research & Manufacturers of America official said
Confidential Clinical Trial Database Could Spur Publication – Ex-PhRMA Exec
Creating a database of clinical trial information that would be accessible to journal editors, but not the public, could help encourage companies to publish certain types of trial information, a former Pharmaceutical Research & Manufacturers of America official said
PhRMA Expects Study Results Database To Be Fully Populated By October
The Pharmaceutical Research & Manufacturers of America expects full participation from all association members in the PhRMA-sponsored database ClinicalStudyResults.org by October